RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-phase trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:33 UTC
-
Can nivolumab rescue patients when CAR T-Cell therapy fails?
Disease control CompletedThis study tested the drug nivolumab in 20 people with blood cancers (like lymphoma, leukemia, or myeloma) that came back or didn't respond after CAR T-cell therapy. Nivolumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal was to see ho…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 10:31 UTC